This content is machine translated Primary immunodeficiency Adventure with IGI – Primary immunodeficiency explained in a playful way With young patients, it is often a challenge for the physician to explain a complex disease in an understandable way to parents and child. On the new website www.leben-mit-pid.ch, the…
View Post 4 min This content is machine translated Dupilumab in atopic dermatitis New post-hoc analysis: consistent symptom improvement over 52 weeks. In atopic dermatitis, long-term symptom control is one of the overriding therapeutic goals. A recently published post-hoc analysis demonstrated that patients treated with dupilumab achieved sustained and consistent improvement in…
View Post 3 min This content is machine translated Case Report Subcorneal pustular dermatosis Also known as Sneddon-Wilkinson syndrome, this rare disorder is characterized by primary pustular changes predominantly in the trunk and proximal extremities. Histopathologic examination complementary to physical inspection and history allows…
View Post 4 min This content is machine translated Moderate to severe atopic dermatitis IL-13 blockade – an innovative treatment approach with great potential The spectrum of systemic treatment options for atopic dermatitis is currently in flux. In recent years, the interleukin (IL)-13 pathway has been shown to play an essential role in the…
View Post 4 min This content is machine translated Upper respiratory tract comorbidities When asthma and rhinosinusitis go hand in hand Almost half (45%) of all patients with – mainly severe – asthma are also affected by chronic rhinosinusitis with nasal polyps (CRSwNP). As many as 60% have allergic rhinitis as a…
View Post 5 min This content is machine translated New S3 guideline Clear focus on primary allergy prevention When it comes to allergy prevention, what are the priorities for supplemental feeding? How should the administration of cow’s milk-based formula be evaluated? Are supplements a reliable preventive measure? And…
View Post 4 min This content is machine translated Atopic dermatitis: biologics Dupilumab also effective and safe in under 12-year-olds In Switzerland, the approval of the highly effective biologic Dupilumab in the indication area of atopic dermatitis has so far been limited to adult and adolescent patients aged 12 years…
View Post 3 min This content is machine translated Atopic dermatitis: JAK inhibitors Baricitinib combined with topical steroids achieves high patient benefit When topical steroid therapy alone is not sufficiently effective, patients with atopic dermatitis may benefit greatly from the additional use of the JAK inhibitor baricitinib. This is shown, among other…
View Post 4 min This content is machine translated Chronic spontaneous urticaria When antihistamines are not enough – ligelizumab soon available in addition to omalizumab? The biologic omalizumab has empirically well-documented efficacy and safety and is considered the treatment of choice in international guidelines for cases of chronic spontaneous urticaria with inadequate response to antihistamines.…
View Post 4 min This content is machine translated Atopic dermatitis Long-term efficacy of baricitinib proven In adult patients with moderate to severe atopic dermatitis, long-term therapy with the JAK inhibitor baricitinib maintained improvements achieved after 16 weeks for 68 weeks, new data show. A pooled…
View Post 2 min This content is machine translated Digital Health Neurodermatitis patients benefit from Nia App With the new cooperation between aha! Allergy Center Switzerland and Nia Health, more sufferers in Switzerland should use the award-winning app in their daily lives. The focus is on the…
